The Latest Breaking News from FOLD

From a mattress topper that will transform your sleep to an at-home Reformer Pilates machine, Jessica Salter on the tech we will all be coveting this year

Still haven’t organised a solid New Year’s Eve Plan? Here’s a handpicked list of the best club nights to ring in 2025

Advanced medical technologies and the pivotal role of technology in drug development are poised to drive significant growth in the biotech industry. Against this backdrop, should you buy, sell or hold biotech stocks Moderna (MRNA), MacroGenics (MGNX), and Amicus Therapeutics (FOLD)? Let’s find out….

Healthcare is considered a reliable defensive sector. So, amid the current uncertain economic landscape, let's determine the more favorable investment option between two prominent pharmaceutical companies, Moderna (MRNA) and Amicus Therapeutics (FOLD). Keep reading.

The ever-rising demand for quality healthcare is expected to benefit the biotech industry. Moreover, favorable government initiatives to boost domestic biotech research and production should boost the industry’s prospects. Therefore, it could be wise to buy fundamentally strong biotech stocks Shionogi & Co. (SGIOY), Amicus Therapeutics (FOLD), and Entrada Therapeutics…

With the biotech industry experiencing significant growth due to the increasing demand for healthcare solutions, fundamentally sound stocks such as Amicus Therapeutics (FOLD), POINT Biopharma Global (PNT), and Precision BioSciences (DTIL) might have the potential to provide substantial returns for investors and could be valuable portfolio additions this month. Learn…

The biotech industry is well-positioned to witness significant growth due to technological advancements and government spending. Moreover, given the sector’s defensive nature, biotech stocks Amicus Therapeutics (FOLD), Corcept Therapeutics (CORT), and Harmony Biosciences (HRMY) might be solid buys in 2023. Read on.

The Pixel Fold is Google's first foray into the foldable space brings an incredibly slim design, beyond all-day battery life and Google's excellent camera at an eye-watering price.

Given the breakthrough developments and government initiatives, the biotech industry is well-positioned to grow steadily. Therefore, fundamentally strong biotech stocks Amicus Therapeutics (FOLD) and POINT Biopharma (PNT) could be worth buying now. Read on.